Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form SC 13G/A

BIOSANTE PHARMACEUTICALS INC Form SC 13G/A February 16, 2010

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SCHEDULE 13G /A (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No. 1)*

BioSante Pharmaceuticals, Inc. (Name of Issuer)

Common Stock (Title of Class of Securities)

09065V203 (CUSIP Number)

December 31, 2009 (Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- ý Rule 13d-1(c)
- o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but

shall be subject to all other provisions of the Act (however, see the Notes).

Page 1of 8 Pages

CUSIP No.	09065V2	03		13G /A	Page 2 of 8 Pages	
	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
2 (A B	TANG CAPITAL PARTNERS, LP CHECK THE (a) APPROPRIATE (b) ý BOX IF A MEMBER OF A GROUP*					
3	SEC USE ONLY					
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION					
DELAWARE						
		5	SOLE VOTING POW	ER		
NUMBEI	R OF		0			
SHARI BENEFICI	ALLY	6	SHARED VOTING P	OWER		
OWNED EACI REPORT PERSON	H 'ING	7	3,845,968 SOLE DISPOSITIVE 0	POWER		
FERSON	vv 1 1 1 1	8	SHARED DISPOSITI	VE POWER		
9 AG	GREGAT	E AMO	3,845,968 UNT BENEFICIALLY	OWNED BY E	ACH REPORTING PERSON	
3,84	45,968					
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

6.7%

12 TYPE OF REPORTING PERSON

PN

Page 2 of 8 Pages

CUSIP	No. 09065V2	203		13G /A	Page 3 of 8 Pages	
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	TANG CA	APITAL	MANAG	EMENT, LLC		
2	CHECK T APPROPR BOX IF A OF A GRO	THE IATE MEMB	(b)	ý		(a)
3	SEC USE	ONLY				
4	CITIZEN	SHIP O	R PLACE	OF ORGANIZATION		
	DELAWA	ARE				
		5	SOLE V	OTING POWER		
NUM	BER OF		0			
SHARES 6 BENEFICIALLY		SHARE	D VOTING POWER			
	NED BY		3,845,96			
	ACH ORTING	7	SOLE D	DISPOSITIVE POWER		
	ON WITH		0			
		8	SHARE	D DISPOSITIVE POWER		
			3,845,96	58		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	3,845,968					
10	CHECK BO	X IF TH	E AGGRI	EGATE AMOUNT IN ROV	V (9) EXCLUDES CERTAIN SHARE	S
11	PERCENT C	OF CLA	SS REPRE	ESENTED BY AMOUNT I	N ROW 9	
	6.7%					

00

TYPE OF REPORTING PERSON

Page 3 of 8 Pages

12

CUSIP	No. 09065V2	203		13G /A	Page 4 of 8 Pages	
1	1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
2	KEVIN C. TANG					
3	SEC USE ONLY					
4	CITIZEN	SHIP C	R PLACE OF ORGA	NIZATION		
	UNITED STATES					
		5	SOLE VOTING PC	OWER		
NUM	BER OF		0			
	ARES	6	SHARED VOTING	POWER		
BENEFICIALLY OWNED BY			3,845,968			
EACH		7	SOLE DISPOSITIV	E POWER		
	ORTING ON WITH		0			
		8	SHARED DISPOSI	TIVE POWER		
			3,845,968			
9						
	3,845,968					
10						
11	PERCENT C	OF CLA	SS REPRESENTED I	BY AMOUNT IN	ROW 9	
	6.7%					
12	TYPE OF REPORTING PERSON					

IN

Page 4 of 8 Pages

..

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form SC 13G/A

Item 1(a).		Name of Issuer:
		BioSante Pharmaceuticals, Inc.
Item 1(b).		Address of Issuer's Principal Executive Offices:
		111 Barclay Blvd., Lincolnshire, IL 60069
Item 2(a).		Name of Person Filing:
		This Statement on Schedule 13G /A (this "Statement") is filed by Tang Capital Partners, LP ("Tang Capital Partners"); Tang Capital Management, LLC, the general partner of Tang Capital Partners ("Tang Capital Management"); and Kevin C. Tang, the manager of Tang Capital Management.
Item 2(b).		Address of Principal Business Office or, if none, Residence:
		4401 Eastgate Mall, San Diego, CA 92121
Item 2(c).		Citizenship:
		Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.
Item 2(d).		Title of Class of Securities:
		Common Stock
Item 2(e).		CUSIP Number: 09065V203
Item 3.	Not applicable.	
Item 4.	Ownership.	
	(a)	Amount Beneficially Owned:
		Tang Capital Partners. Tang Capital Partners is the beneficial owner of \$14,307,000 principal face amount of the Issuer's 3.125% Convertible Senior Notes due 2013 (the "Notes"). The Notes are convertible into the Issuer's common stock at a conversion rate of 268.8172 shares of common stock per \$1,000 principal face amount of the Notes. Therefore, Tang Capital Partners beneficially owns the 3,845,968 shares of the Issuer's common stock issuable upon conversion of the Notes, or 6.7% of the class. Tang Capital Partners shares voting and dispositive power over such Notes with Tang Capital Management and Kevin C. Tang.

Tang Capital Management. Tang Capital Management, as the general partner of Tang Capital Partners, may be deemed to beneficially own the 3,845,968 shares of the Issuer's common stock issuable upon conversion of the Notes held by Tang Capital Partners, or 6.7% of the class. Tang Capital Management shares voting and dispositive power over such Notes with Tang Capital Partners and Kevin C. Tang.

Page 5 of 8 Pages

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form SC 13G/A

Kevin C. Tang. Kevin C. Tang, as the manager of Tang Capital Management, may be deemed to beneficially own the 3,845,968 shares of the Issuer's common stock issuable upon conversion of the Notes held by Tang Capital Partners, or 6.7% of the class. Kevin C. Tang shares voting and dispositive power over such Notes with Tang Capital Partners and Tang Capital Management.

Mr. Tang disclaims beneficial ownership of all shares reported herein except to the extent of his pecuniary interest therein.

The percentages used herein are based upon 57,108,864 shares of common stock outstanding as of December 31, 2009 (53,262,896 shares outstanding as of November 1, 2009, as reported by the Issuer on the Form 10-Q as filed with the Securities and Exchange Commission on November 09, 2009, plus the 3,845,968 shares of common stock issuable upon the conversion of the Notes held by Tang Capital Partners).

(b) Percent of Class:

Tang Capital Partners	6.7%
Tang Capital Management	6.7%
Kevin C. Tang	6.7%

(c) Number of shares as to which such person has:

(i)	sole power to vote or to direct the vote:	
	Tang Capital Partners	0 shares
	Tang Capital Management	0 shares
	Kevin C. Tang	0 shares
(ii)	shared power to vote or to direct the vote:	
	Tang Capital Partners	3,845,968 shares
	Tang Capital Management	3,845,968 shares
	Kevin C. Tang	3,845,968 shares
(iii)	sole power to dispose or to direct the disposition of:	
	Tang Capital Partners	0 shares
	Tang Capital Management	0 shares
	Kevin C. Tang	0 shares
(iv)	shared power to dispose or to direct the disposition of:	
	Tang Capital Partners	